NFE2L2 and relapsing-remitting multiple sclerosis: One striking example of successful clinical development of Nrf2-modulating drugs is use of dimethyl fumarate (DMF/TecfideraTM) which currently is a leading first-line treatment for relapsing remitting multiple sclerosis (RRMS) worldwide [10–12].